Arkolith/Insider Trading/ATHA/Form 4

Gengos Andrew

CFO and Chief Business OfficerAthira Pharma, Inc. (ATHA) · full profile →Form 4 · filed Sep 5, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$725
Net Open-Market Flow
-$725
Transactions
3
3 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 5, 2024Sell(S)1K$0.57$72598K
Sep 3, 2024Grant(A)5K—$099K
May 20, 2024Grant(A)10K$1.34$13K94K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-24-022987) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML